Celldex Therapeutics, Inc.
CLDX
$27.81
$1.144.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -70.78% | 345.51% | -71.56% | 110.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -70.78% | 345.51% | -71.56% | 110.35% |
| Cost of Revenue | 39.03% | 36.56% | 66.18% | 54.27% | 31.06% |
| Gross Profit | -49.58% | -43.77% | -64.80% | -74.04% | -27.42% |
| SG&A Expenses | 6.29% | 13.84% | 18.86% | 16.20% | 22.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.08% | 32.31% | 55.61% | 45.71% | 29.38% |
| Operating Income | -41.23% | -37.87% | -54.50% | -59.50% | -26.40% |
| Income Before Tax | -59.17% | -57.92% | -63.97% | -8.74% | -10.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.17% | -57.92% | -63.97% | -8.74% | -10.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.17% | -57.92% | -63.97% | -8.74% | -10.09% |
| EBIT | -41.23% | -37.87% | -54.50% | -59.50% | -26.40% |
| EBITDA | -41.79% | -38.37% | -55.33% | -60.64% | -26.85% |
| EPS Basic | -58.86% | -57.03% | -45.42% | 14.74% | 21.51% |
| Normalized Basic EPS | -58.88% | -57.03% | -45.42% | -19.86% | 21.52% |
| EPS Diluted | -58.86% | -57.03% | -45.42% | 14.74% | 21.51% |
| Normalized Diluted EPS | -58.88% | -57.03% | -45.42% | -19.86% | 21.52% |
| Average Basic Shares Outstanding | 0.19% | 0.56% | 12.76% | 27.53% | 40.27% |
| Average Diluted Shares Outstanding | 0.19% | 0.56% | 12.76% | 27.53% | 40.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |